Overview

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Synergy Pharmaceuticals Inc.
Collaborators:
INC Research
Syneos Health
Treatments:
Plecanatide